Over 50 Years of Specialty Injectables
American Regent develops, manufactures and supplies high-quality sterile injectables for healthcare providers and their patients.
Dedicated to Alleviating Drug Shortages
We are committed to collaborating with the FDA to prevent or mitigate drug shortages that impact the health of patients.
Check Product Availability
Updated June 22, 2021 09:21 AM
Atropine Sulfate
- 0.4 mg/mL | 1 mL Single Dose Vial
- Shelf Pack — 25
HydrALAZINE Hydrochloride
- 20 mg/mL | 1 mL Single Dose Vial
- Shelf Pack — 25
Papaverine HCL
- 30 mg/mL | 2 mL Single Dose Vial
- Shelf Pack — 25
Zinc Sulfate
- 5 mg/mL | 5 mL Pharmacy Bulk Package Vial
- Shelf Pack — 25
News Center
Injectafer® (ferric carboxymaltose injection) Receives FDA Approval for Single Dose Option for the Treatment of Adult Patients with Iron Deficiency Anemia
Basking Ridge, N.J. and Shirley, N.Y. (May 6, 2021): Daiichi Sankyo, Inc. and American Regent, Inc., a Daiichi Sankyo Group company, today announced that the U.S. Food and Drug Administration (FDA) has approved a single 1000 mg dose option of Injectafer® (ferric carboxymaltose injection), an iron replacement product, for the treatment of iron deficiency anemia (IDA) in adult patients who have intolerance to oral iron, have had unsatisfactory response to oral iron, or have non-dialysis dependent chronic kidney disease (CKD).1
American Regent, Inc. Announces New CEO
Shirley, NY – April 1, 2021: Paul Diolosa assumed the role of President and CEO of American Regent, Inc., a Daiichi Sankyo Group company, effective today.
American Regent, Inc. introduces Tralement® (trace elements injection 4*, USP)
Melville, NY – September 30, 2020: American Regent, Inc. announces the introduction of Tralement® (trace elements injection 4*, USP), the first and only FDA-approved multi-trace element injection.